Emilie Klein

10PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)HaematologyCellular immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 04, 2026
Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

|Feb 02, 2026
Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.

Audrey Bidet, Elodie Laharanne, Manon Dos Santos

|Jan 29, 2025
Relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia responds well to a combination of modified hyper-CVAD, blinatumomab and tyrosine kinase inhibitor.

Gaétan Basile, Jean Galtier, Titouan Cazaubiel

|Nov 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

Christian Récher, Pierre-Yves Dumas, Emilie Bérard

|Feb 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.

Harmony Leroy, Noémie Gadaud, Emilie Bérard

|Apr 02, 2023
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.

Stéphanie Dulucq, Françoise Rigal-Huguet, Franck E Nicolini

Pageof 2

Frequent Collaborators

4 joint publications

Pierre-Yves Dumas

3 joint publications

Gabriel Etienne

3 joint publications

Audrey Bidet

3 joint publications

Christian Récher